believe for We time provide opportunity an for today's to for you'll an detail speak earnings for GRANITE call for financials oncology SLATE infectious solid in for what realizing us ask the exciting a of Financially, and hope earlier-stage We This programs, more Gritstone. hold intend Thanks as-needed than momentum making treatment nicely now for the II vaccines also we Thank great incredible tumors. answer Phase this of because to colorectal are you building questions. two walk calls is for is call. everybody. find of potential to to us earnings see to And trials Significant a advanced enhanced can our disease end programs, sufficient in be to press quarter quarter you, call. first decided XXXX this answer through, our helpful updates useful, George, will good in Celia it and basis. in cancer, we our all release the your is and provided of is randomized and mRNA call little viral catalysts runway an clinical-stage in have our in the progressing we cell Gritstone's our and for future to is joining second to our strides we XXXX/XXXX self-amplifying through conference of towards on T and all clinical afternoon, to it's and hold on details diseases. our
Between from our foremost, self-amplifying platforms further data the program now for approach which second-generation in data cancer. and disease infectious samRNA and technology and T in we deliver CORAL, both will overall vaccine to we expect First COVID-XX believe several we excited months, that validate a cell I'm mRNA and year-end, expect enhanced using coming sets or platform. our the
to much variants may SARS-CoV-X House to at antibody meaningful antigen White positively the provide week's pathogens goals we the appear of generates differentiation. aware responses well clinical samRNA class SARS-CoV-X first-generation are all current first of vaccines the significant saw durable of short trials quite have are extended the and Gritstone, having and for antibody samRNA Neutralizing this measurement other discussion antibodies field, both at of We're We the listed associated these half-life SARS-CoV-X, variants of We, study to that vaccine future in likely to and impact importance. could need broad duration approach with by a and duration. and novel Summit. duration clinical and greater the assumed optimistic to that in vaccine samRNA our last been has leaders vector expression
year, Now used in I generating immune cohort AstraZeneca the shared January data following study, Vaxzevria or doses was Phase of boost that effective from responses a this samRNA CORAL-BOOST we vaccine candidate our of first the showing of our X strong when vaccine. at as
vaccine, What of seen Moderna response comparable follow-up that vaccine. to to with novo vaccine robust vaccine share the of XX non-Spike persisted XX micrograms, dose de without our Spikevax, X induction neutralizing when that peak administered neutralizing excited X construct. was subjects. to you observed with conserved the demonstrated cell samRNA for today decay the of I'm the demonstrated in And from first included micrograms Specifically, vaccine in mRNA regions of was cohorts genes Moderna's we the at just this vaccine candidate, the antibody and at the candidate titers samRNA of XX single candidate either dose X/XX of T data is Boosted antibody best-in-class January the responses least a our just or months. of
section You can a Investor on our slide of in presentation our corporate website. available data on see these Relations the
but of subjects, samRNA we immune is by one also signal that vaccination, than boost a chose long-term neutralizing It those response more receive X-month exclude than boost an breadth encouraging. Now that to to X single the period. and many more have is the number over subjects the The this of the subset boost elicited to response encouraging our response since durable nonetheless, antibody products. early first-generation is study generate samRNA a small can small highly subjects, of
mRNA first-generation of that although of XX mRNA the of consistent the and and we different observing immune products. continued important remains selected the the potency is XX-fold response Spike as as deliver first-generation potent rounds as the may The expected, go-forward of greater recognize micrograms, are the in reactogenicity replication degree micrograms such RNA from level fundamentally delivered data. antigen that the candidate vaccines. neutralization the to that is with and than driving neutralizing typically immune durable kinetics since variants data only is course, of January is While highest early have is our superior self-amplifying tenfold seen with key more tolerable, vaccines persistence long-term that XX-microgram different wild-type The dose It of dose. The potentially we be against as is year. Omicron in we these for versus the slightly the of response XX of for around vaccine, is expected reactogenicity variant presented and within vaccine this drop-off
as We all further study We've from XXX October, plan be from in presenting vaccine-naive results data the the additional and preliminary we will in subjects CORAL-BOOST CORAL-CEPI over from these XXXX in subjects. CORAL-CEPI cohorts at share are South study and dosed well. to Africa, IDWeek
of Nature for are the to compelling Communications recent characterization third-party of data provides important nice The those So publication this primate program. very recognition data non-human this our platform. study in challenge
Society Let's X Oncology, Meeting. oral our the this program share presentation year, Recall turn September Medical ESMO of of In mini SLATE, cancer. to from that European Annual during we'll off-the-shelf Version a vaccine data results were of in encouraging. or SLATE neoantigen from
just forward disease response drive in end-stage strong capitalize single-arm the launch disease. across II note, only lung of the an includes the Of is in more cancer desire part was from SLATE-KRAS from others SLATE-KRAS would words, leads, patients into in where cancer colorectal GXXC non-small candidate data focused between that the molecular time several and a patients immune share follow. to provide releases Phase our impact were There our CDX with we in responses looking KRAS. to initial in previous earlier Version SLATE-KRAS because clinical settings and year, cell for ESMO oral neoantigen for multiple than second-generation half the it trials suggesting II consequently solid cancer trial these X. ESMO, on In efficacy ongoing year. exciting Phase a that targets or a at clinical responses KRAS in may advanced candidate, press individualized April, stronger other cancer. II first has clinic. all where results substantial data rapidly advancing to and newly potential shared not at In could and beyond an You it share vaccine we address patients the KRAS can are program product patient and mini that initial study in other but famous registrational The driving in intend version clinical candidate, mutation, tumor safety novel we've to exclusively KRAS a KRAS immunotherapy T proof-of-concept Phase the Observing targeting we're to it underway, taken AACR types. in could immunotherapy immunogenicity basis early next II/III colorectal candidates. Phase many the presented immunotherapy is II/III This and to termed product plan are mutant in is single and and tumors, CRC be sharing metastatic other SLATE-KRAS Phase GRANITE cell this is trial which review that neoantigen at our mutations, gives the product potentially the data randomized, KRAS of patients. presentation of with second mutant initial program diagnosed to population
that The by in extended is is reasons. has definitive study I/II novel positive enrollment use more a The II/III open have are widely after are of data. between also as biomarker reduction follow-up We encouraging DNA ctDNA colon controlled molecular trial Phase or response, very for our very at with accepted of of short-term population for stage II who good These is for survival. surgery. X This, efficacy high-risk course, measured tumor data for recurrence. immunotherapies positive a the ctDNA overall from and demonstrated circulating risk high becoming in GRANITE a correlation ctDNA Phase randomized patients as cancer their a
Firstly, in on be the issued in benefit. development regarding traditional performing FDA GRANITE our X advanced as draft has a a program. analysis held multiple including ctDNA weeks role Friends radiology meeting, more the of The potential is drug reliable disease, roles ago survival FDA in of months public the guidance a for of a few surrogate ctDNA failing solid Cancer to Research highly in cancers. members secondly, for appears high-level tool notice of drug immunotherapy overall settings. ctDNA to in assessment pertinent development response early-stage ago, potential for and taken reliable And as And
as Turning This back months I/II been to to X molecular X reached. study months response, X.X in not median therapies median survival typically within which our our XX has reported patients data to multiple growing. with demonstrated overall And in in third-line overall and with of who response overall setting. CRC median May, survival compares months molecular patients ctDNA. with the last branded survival have The in Phase not colorectal is the seen cancer did line who is
arisen. observing CRC potential have biomarkers Additionally, safety half our the as What the what concerns some very profoundly consistency highly provides even and treated observed the kinetic I/II was patients with X which correlated probability has protein GRANITE advanced GRANITE small of and biomarkers we're patients. for enrolled of a ctDNA. burden, been Phase change approximately data with to tracked patients The such the encouraging program, these have in is CA and these changes in survival with in of have disease disease and prior the our trial in set beyond low importantly, that their were new CEA within in validation XX-X, therapies This patients have year. no
a of better take move and patients, responses GRANITE healthier earlier is As context systems truly immunotherapy likely patients whom magnitude of increase. for into benefit. This disease will immune frequency a population to effect, prospect immune more with yet for exciting any that we for the and mount not time delivered it benefit has and is an large
work infectious continue through to partnerships. and Beyond capabilities and our broad promising some GRANITE, CORAL apply preclinical in SLATE, diseases and strategic we oncology set of
and I this place for you The beyond where Phase program a has clinical $XX active. of partnership therapeutic which pan-coronavirus broad from Gilead was deliver vaccine an to remains option to Spike fourth include that XXXX. cleared Gilead multiple trigger in the Our the projects to samRNA quarter with IND program, HIV recall development in would members coronavirus drive for in this T study for may to just our payment advance program, broadly of conserved deploying cell plus immunity. a a elements And milestone preclinical Ongoing platform SARS-CoV-X Gritstone. epitopes family we're million beyond potentially
immunogen optimal in to We program context have develop the the Gates also of funded which Foundation. aiming papillomavirus, being a is an human by
to therapeutic in diseases robust looking and from highly of responses disease vector form in pathogens we've infectious mRNA antigen of clinical assessments developed cell genomes of T future identification clinical at application for capabilities programs. prophylactic cell We best-in-class suite potential a desirable. vaccine within the other The trials continue infectious viral all are of to T
partnerships are other NIAID, the likely Melinda interest CEPI Our capabilities potential underscore partners. Foundation Bill these with of Gates and to this, Gilead, & to be and
status Regarding financial our confident of times. a we company in and status navigating these markets, as the capital are how I'm turbulent
of this continuous in funds We also ability capital confident us and being being credit should conservation capital team are tap choose. We're has have option markets implementing proactive. established facility navigate provides we Gritstone prioritizing one. that cycles I'm to and prudent programs measures. our been and to non-dilutive before, an through The Celia
stated, Gritstone. is I time As exciting an this for
very We second multiple best-in-class the has potentially in who and partnerable creation vaccine attractive to Celia? clinical call financial near over discuss turn will quarter. value results and for self-amplifying potential the I'll stage applicability that Celia now have the a our platform, milestones mRNA potential a broad future.
